Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP2567
- Development stage
- Preclinical
- Lead developer
- NeoPhore
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NP2567 is a first-in-class, potent, and selective small molecule inhibitor of the DNA mismatch repair (MMR) protein PMS2, currently in preclinical development by NeoPhore. By targeting the MutLα complex (comprising MLH1 and PMS2), NP2567 aims to transiently inhibit the MMR pathway in tumor cells. This inhibition leads to the accumulation of DNA replication errors and the generation of novel neoantigens, thereby increasing the tumor mutational burden (TMB). The therapeutic strategy is designed to transform immunologically "cold" tumors into "hot" tumors, potentially sensitizing them to immune checkpoint inhibitors or other immunotherapies.
- Other names
- NP2567NP-2567NP 2567
02
Targets
PMS2
Beyond the preview
Go deeper on NP2567.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP2567.